Predictive modelling for late rectal and urinary toxicities after prostate radiotherapy using planned and delivered dose

Ashley Li Kuan Ong; Kellie Knight; Vanessa Panettieri; Mathew Dimmock; Jeffrey Kit Loong Tuan; Hong Qi Tan; Caroline Wright

doi:10.3389/fonc.2022.1084311

Predictive modelling for late rectal and urinary toxicities after prostate radiotherapy using planned and delivered dose

Front Oncol. 2022 Dec 16:12:1084311. doi: 10.3389/fonc.2022.1084311. eCollection 2022.

Authors

Ashley Li Kuan Ong^{1

2}, Kellie Knight², Vanessa Panettieri^{2

3}, Mathew Dimmock^{2

4}, Jeffrey Kit Loong Tuan¹, Hong Qi Tan¹, Caroline Wright²

Affiliations

¹ Division of Radiation Oncology, National Cancer Centre, Singapore, Singapore.
² Medical Imaging and Radiation Sciences, Monash University, Clayton, VIC, Australia.
³ Alfred Health Radiation Oncology, Alfred Hospital, Melbourne, VIC, Australia.
⁴ School of Allied Health Professions, Keele University, Staffordshire, United Kingdom.

Abstract

Background and purpose: Normal tissue complication probability (NTCP) parameters derived from traditional 3D plans may not be ideal in defining toxicity outcomes for modern radiotherapy techniques. This study aimed to derive parameters of the Lyman-Kutcher-Burman (LKB) NTCP model using prospectively scored clinical data for late gastrointestinal (GI) and genitourinary (GU) toxicities for high-risk prostate cancer patients treated using volumetric-modulated-arc-therapy (VMAT). Dose-volume-histograms (DVH) extracted from planned (D_P) and accumulated dose (D_A) were used.

Material and methods: D_P and D_A obtained from the DVH of 150 prostate cancer patients with pelvic-lymph-nodes irradiation treated using VMAT were used to generate LKB-NTCP parameters using maximum likelihood estimations. Defined GI and GU toxicities were recorded up to 3-years post RT follow-up. Model performance was measured using Hosmer-Lemeshow goodness of fit test and the mean area under the receiver operating characteristics curve (AUC). Bootstrapping method was used for internal validation.

Results: For mild-severe (Grade ≥1) GI toxicity, the model generated similar parameters based on D_A and D_P DVH data (D_A-D₅₀:71.6 Gy vs D_P-D₅₀:73.4; D_A-m:0.17 vs D_P-m:0.19 and D_A/P-n 0.04). The 95% CI for D_A-D₅₀ was narrower and achieved an AUC of >0.6. For moderate-severe (Grade ≥2) GI toxicity, D_A-D₅₀ parameter was higher and had a narrower 95% CI (D_A-D₅₀:77.9 Gy, 95% CI:76.4-79.6 Gy vs D_P-D₅₀:74.6, 95% CI:69.1-85.4 Gy) with good model performance (AUC>0.7). For Grade ≥1 late GU toxicity, D₅₀ and n parameters for D_A and D_P were similar (D_A-D₅₀: 58.8 Gy vs D_P-D₅₀: 59.5 Gy; D_A-n: 0.21 vs D_P-n: 0.19) with a low AUC of<0.6. For Grade ≥2 late GU toxicity, similar NTCP parameters were attained from D_A and D_P DVH data (D_A-D₅₀:81.7 Gy vs D_P-D₅₀:81.9 Gy; D_A-n:0.12 vs D_P-n:0.14) with an acceptable AUCs of >0.6.

Conclusions: The achieved NTCP parameters using modern RT techniques and accounting for organ motion differs from QUANTEC reported parameters. D_A-D₅₀ of 77.9 Gy for GI and D_A/D_P-D₅₀ of 81.7-81.9 Gy for GU demonstrated good predictability in determining the risk of Grade ≥2 toxicities especially for GI derived D₅₀ and are recommended to incorporate as part of the DV planning constraints to guide dose escalation strategies while minimising the risk of toxicity.

Keywords: Lyman-Kutcher-Burman (LKB) model; accumulated dose; high-risk prostate cancer; image-guided radiotherapy (IGRT); late toxicity complications; normal tissue complication probability (NTCP).